On May 28, 2019, Amgen, along with leading community oncology networks, announced the launch of Amgen Community Oncology Research Collaborators, a new initiative to enhance access by community centers to innovative oncology clinical research.

Fewer than one in 20 adult cancer patients in the U.S. have participated in a clinical trial. The collaboration will allow Amgen to significantly expand its clinical research footprint to more than 200 patient care sites across the U.S. and help community centers reach more than 900,000 new patients each year with investigational medicines.

US Oncology Research and Translational Research In Oncology-US, Inc. (TRIO-US) and its joint work with the University of California, Los Angeles (UCLA) Clinical Research Unit signed on as the first ACORC participants, with plans to include additional networks in 2019.

This collaboration provides community oncologists the opportunity to have their patients participate in clinical trials of investigational agents from Amgen’s pipeline — including bispecific T cell engager (BiTE^®) antibody constructs and novel small molecules.

In addition, the collaboration offers the opportunity to generate data through real-world evidence studies on currently available oncology products.